KaloBios Soars 649% On Turing CEO’s Big Stock Buy

By | November 18, 2015

Scalper1 News

KaloBios Pharmaceuticals (KBIO) skyrocketed 649% to 15.50 in after-hours action following news that Turing Pharmaceuticals CEO Martin Shkreli bought 1.2 million shares of KaloBios. KaloBios topped 17 briefly. KaloBios had 4.1 million shares outstanding as of Aug. 7. Shares were bought Monday-Tuesday at prices from 61 cents to $2.43. On Friday, KaloBios said it would wind down its operations and liquidate assets. Shkreli gained notoriety recently Scalper1 News

Scalper1 News